Literature DB >> 15036563

Alpha-fodrin is cleaved by caspase-3 in a chronic ocular hypertensive (COH) rat model of glaucoma.

N G Tahzib1, N L Ransom, H A Reitsamer, S J McKinnon.   

Abstract

PURPOSE: alpha-Fodrin is a neuronal cytoskeletal protein and a known caspase-3 target. We sought to determine whether caspase-3 cleaves alpha-fodrin in COH rat retinas and whether this process is reduced by adeno-associated virus (AAV)-induced retinal ganglion cell expression of baculovirus inhibitory repeat-containing 4 (BIRC4), a potent caspase-3 inhibitor.
METHODS: Ocular hypertension was induced unilaterally in five rat eyes by limbal injection of hypertonic saline. In a similar experiment, ocular hypertension was induced in four eyes pre-treated with an intravitreal injection of AAV-BIRC4 to assess alpha-fodrin cleavage. Western immunoblotting was performed on all retinas.
RESULTS: Caspase-3 cleavage of alpha-fodrin yields a specific 120kDa protein fragment. COH retina immunoblots indicated significantly more caspase-3 cleavage of alpha-fodrin than controls (P < 0.01, paired t-test). Inhibition of retinal caspase-3 activity with BIRC4 reduced caspase-3-mediated alpha-fodrin cleavage compared to controls.
CONCLUSIONS: This confirms our previous finding of caspase-3 cleavage of alpha-fodrin in COH retinas and parallels pathology seen in Alzheimer's disease, in which neurons undergo chronic caspase activation, slow build-up of cleavage products, and delayed apoptosis. If caspase activation in glaucoma leads to protracted rather than rapid retinal ganglion cell apoptosis, a much longer therapeutic window exists for apoptosis inhibition with caspase inhibitors such as BIRC4.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15036563     DOI: 10.1016/S0361-9230(03)00083-2

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  12 in total

1.  A precise temporal dissection of monosodium glutamate-induced apoptotic events in newborn rat retina in vivo.

Authors:  Viktória Dénes; Mónika Lakk; Nikoletta Czotter; Róbert Gábriel
Journal:  Neurochem Res       Date:  2011-04-22       Impact factor: 3.996

2.  Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action.

Authors:  Grace C Shih; David J Calkins
Journal:  Expert Rev Ophthalmol       Date:  2012-04

Review 3.  Neurodegeneration in glaucoma: progression and calcium-dependent intracellular mechanisms.

Authors:  S D Crish; D J Calkins
Journal:  Neuroscience       Date:  2010-12-25       Impact factor: 3.590

Review 4.  Pharmacological neuroprotection for glaucoma.

Authors:  Glyn Chidlow; John P M Wood; Robert J Casson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 5.  Gene therapy targeting glaucoma: where are we?

Authors:  Xuyang Liu; Carol A Rasmussen; B'ann T Gabelt; Curtis R Brandt; Paul L Kaufman
Journal:  Surv Ophthalmol       Date:  2009 Jul-Aug       Impact factor: 6.048

Review 6.  Immunological mechanisms in glaucoma.

Authors:  F Grus; D Sun
Journal:  Semin Immunopathol       Date:  2008-03-11       Impact factor: 9.623

7.  Calpain activation in experimental glaucoma.

Authors:  Wei Huang; John Fileta; Ian Rawe; Juan Qu; Cynthia L Grosskreutz
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-27       Impact factor: 4.799

8.  The neuronal EGF-related gene Nell2 interacts with Macf1 and supports survival of retinal ganglion cells after optic nerve injury.

Authors:  Yasunari Munemasa; Chang-Sheng Chang; Jacky M K Kwong; Haksu Kyung; Yasushi Kitaoka; Joseph Caprioli; Natik Piri
Journal:  PLoS One       Date:  2012-04-04       Impact factor: 3.240

Review 9.  Retinal Cell Degeneration in Animal Models.

Authors:  Masayuki Niwa; Hitomi Aoki; Akihiro Hirata; Hiroyuki Tomita; Paul G Green; Akira Hara
Journal:  Int J Mol Sci       Date:  2016-01-15       Impact factor: 5.923

10.  Caspase-7: a critical mediator of optic nerve injury-induced retinal ganglion cell death.

Authors:  Shreyasi Choudhury; Yang Liu; Abbot F Clark; Iok-Hou Pang
Journal:  Mol Neurodegener       Date:  2015-08-26       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.